<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00753272</url>
  </required_header>
  <id_info>
    <org_study_id>106372</org_study_id>
    <nct_id>NCT00753272</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older</brief_title>
  <official_title>Observer-blind Superior Efficacy Trial With GlaxoSmithKline Biologicals' Influenza Vaccine GSK2186877A in Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of GlaxoSmithKline Biologicals'
      influenza vaccine GSK2186877A in adults 65 year of age and older. The study design is divided
      in two surveillance phases: one passive phase along the study during the influenza season and
      one active surveillance phase during the influenza peak season.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Protocol Posting has been updated according to Protocol Amendment 3, Sep 2009.

      After the analyses for this study were completed, questions arose regarding the integrity of
      study data from a single study site in Romania, which enrolled 102 subjects in the trial.
      Because evaluation of data from this site did not reveal irregularities when compared with
      overall study data and because GSK has no current plans to use the data from the study in
      support of any regulatory filings, they were not excluded from the analyses reflected in this
      results summary.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2008</start_date>
  <completion_date type="Actual">January 5, 2011</completion_date>
  <primary_completion_date type="Actual">June 18, 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Reporting Polymerase Chain Reaction (PCR)-Confirmed Influenza A and/or B Infection.</measure>
    <time_frame>After the first dose during the corresponding surveillance period (from mid November 2008 to the end of April 2009 (end of influenza season))</time_frame>
    <description>Occurrence of PCR-confirmed influenza A and/or B infection, due to any matching or drift influenza strain relative to the vaccine strains (i.e. not emerging novel human influenza strain like H1N1v). PCR-confirmed influenza (PCI) was defined as an episode of influenza-like illness (ILI) occurring after the administration of the study vaccine for which a nasal and throat swab specimen yields influenza virus A and/or B by reverse transcription polymerase chain reaction (RT-PCR) analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Hemagglutination-inhibition (HI) Antibody Titers, Against Each of the 3 Vaccine Influenza Strains, in the FluNG Groups.</measure>
    <time_frame>At Days 0 (pre-vaccination Dose 1) and 21 (post-vaccination Dose 1) of the first year (2008/2009) of the study</time_frame>
    <description>Vaccine strains assessed were A/Brisbane/59/2077, A/Uruguay/716/2007 and B/Brisbane/3/2007. Titers were expressed as geometric mean titers calculated on all subjects in the lot-to-lot subset of subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Polymerase Chain Reaction (PCR)-Confirmed Influenza A and/or B Infection.</measure>
    <time_frame>During the whole surveillance period (from mid November 2008 to end of April 2009 and from mid November 2009 to end of April 2010)</time_frame>
    <description>Occurrence of PCR-confirmed influenza A and/or B infection, due to any matching or drift influenza strain relative to the vaccine strains (i.e. not emerging novel human influenza strain like H1N1v). PCR-confirmed influenza (PCI) was defined as an episode of influenza-like illness (ILI) occurring after the administration of the study vaccine for which a nasal and throat swab specimen yields influenza virus A and/or B by reverse transcription polymerase chain reaction (RT-PCR) analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Culture-confirmed Influenza A and/or B Infection.</measure>
    <time_frame>During the whole surveillance period (from mid November 2008 to end of April 2009 and from mid November 2009 to end of April 2010)</time_frame>
    <description>Occurrence of culture-confirmed influenza A and/or B infection, due to any matching or drift influenza strain relative to the vaccine strains (i.e. not emerging novel human influenza strain like H1N1v). Culture-confirmed influenza (CCI) was defined as an episode of ILI occurring after the administration of the study vaccine for which a nasal and throat swab specimen yields influenza virus A and/or B by viral culture analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Pneumonia or Clinical Influenza After the First Dose of Vaccine.</measure>
    <time_frame>During the influenza peak season within the first surveillance period (the influenza peak season being defined per country, falling somewhere between mid November 2008 to end of April 2009)</time_frame>
    <description>Clinical influenza= An ILI episode (with an ILI onset from the 15th of November until the end of the surveillance period) with at least simultaneously fever (oral temperature of â‰¥37.8 degrees Celsius) and cough.
The influenza peak season = period during the study with the highest incidence of any matching or drift influenza strain relative to the vaccine strains (i.e. not emerging novel human influenza strain like H1N1v).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting All-cause Death After the First Dose of Vaccine.</measure>
    <time_frame>During the influenza peak season within the first surveillance period (the influenza peak season being defined per country, falling somewhere between mid November 2008 to end of April 2009)</time_frame>
    <description>The influenza peak season = period during the study with the highest incidence of any matching or drift influenza strain relative to the vaccine strains (i.e. not emerging novel human influenza strain like H1N1v).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Hospitalization Due to Respiratory Diseases After the First Dose of Vaccine</measure>
    <time_frame>During the influenza peak season within the first surveillance period (the influenza peak season being defined per country, falling somewhere between mid November 2008 to end of April 2009)</time_frame>
    <description>Respiratory disease: A diagnosis of respiratory disease included: acute respiratory infections, other diseases of upper respiratory tract, pneumonia and influenza, chronic obstructive pulmonary disease and allied conditions, pneumoconioses and other lung diseases due to external agents, other diseases of respiratory system. In case the event has a fatal outcome, the diagnosis can also be confirmed by autopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Severe (Grade 3) and Related to Vaccination Adverse Events (AEs) of Specific Interest Including Autoimmune Disease (AID).</measure>
    <time_frame>Within 365 days after the first dose (from Dose 1 at Day 0 up to Day 365 for the Year 2008/2009)</time_frame>
    <description>Adverse events of specific interest for safety monitoring are a subset of AEs that included both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.
Grade 3 = event that prevented normal everyday activities Related = event assessed by the investigator as causally related to the study vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Severe (Grade 3) and Related to Vaccination Adverse Events (AEs) of Specific Interest Including Autoimmune Disease (AID).</measure>
    <time_frame>Within 365 days after the second dose (from Dose 1 at Day 0 up to Day 365 for the Year 2009/2010)</time_frame>
    <description>Adverse events of specific interest for safety monitoring are a subset of AEs that included both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.
Grade 3 = event that prevented normal everyday activities Related = event assessed by the investigator as causally related to the study vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Severe (Grade 3) and Related to Vaccination Adverse Events (AEs) of Specific Interest Including Autoimmune Disease (AID).</measure>
    <time_frame>During the entire study period (during the 365 days of follow-up after each vaccination at Year 2008/2009 and Year 2009/2010)</time_frame>
    <description>Adverse events of specific interest for safety monitoring are a subset of AEs that included both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.
Grade 3 = event that prevented normal everyday activities Related = event assessed by the investigator as causally related to the study vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Related to Vaccination Serious Adverse Events (SAEs).</measure>
    <time_frame>During the entire study period (during the 365 days of follow-up after each vaccination at Year 2008/2009 and Year 2009/2010)</time_frame>
    <description>SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.
Related = event assessed by the investigator as causally related to the study vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Severe (Grade 3) Solicited Local Symptoms.</measure>
    <time_frame>During the 7-day (Days 0-6) post-vaccination period, the first year (2008/2009)</time_frame>
    <description>Solicited local symptoms assessed were ecchymosis, pain, redness and swelling. Any = incidence of a particular symptom regardless of intensity grade. Grade 3 pain = considerable pain at rest that prevented normal everyday activities. Grade 3 ecchymosis/redness/swelling = ecchymosis/redness/swelling above 100 millimeter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Any Grade of Solicited Local Symptoms</measure>
    <time_frame>During the 7-day (Days 0-6) post-vaccination period, the first year (2008/2009)</time_frame>
    <description>Solicited local symptoms assessed were ecchymosis, pain, redness and swelling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Severe (Grade 3) Solicited Local Symptoms</measure>
    <time_frame>During the 7-day (Days 0-6) post-vaccination period, the second year (2009/2010)</time_frame>
    <description>Solicited local symptoms assessed were ecchymosis, pain, redness and swelling. Any = incidence of a particular symptom regardless of intensity grade. Grade 3 pain = considerable pain at rest that prevented normal everyday activities. Grade 3 ecchymosis/redness/swelling = ecchymosis/redness/swelling above 100 millimeter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Any Grade of Solicited Local Symptoms.</measure>
    <time_frame>During the 7-day (Days 0-6) post-vaccination period, the second year (2009/2010)</time_frame>
    <description>Solicited local symptoms assessed were ecchymosis, pain, redness and swelling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Severe (Grade 3) and Related to Vaccination Solicited General Symptoms</measure>
    <time_frame>During the 7-day (Days 0-6) post-vaccination period, the first year (2008/2009)</time_frame>
    <description>Solicited general symptoms assessed were arthralgia, fatigue, gastrointestinal, headache, myalgia, shivering and temperature (defined as oral temperature equal to or above (â‰¥) 38.0 degrees Celsius). Any = incidence of a particular symptom regardless of intensity grade or relationship to vaccination. Grade 3 = general symptom which prevented normal everyday activities. Related = general symptom assessed by the investigator as causally related to the study vaccination. Grade 3 temperature = oral temperature â‰¥39.0Â°C - â‰¤ 40.0Â°C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Any Grade of Solicited General Symptoms</measure>
    <time_frame>During the 7-day (Days 0-6) post-vaccination period, the first year (2008/2009)</time_frame>
    <description>Solicited general symptoms assessed were arthralgia, fatigue, gastrointestinal, headache, myalgia, shivering and temperature.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms.</measure>
    <time_frame>During the 7-day (Days 0-6) post-vaccination period, the second year (2009/2010)</time_frame>
    <description>Solicited general symptoms assessed were arthralgia, fatigue, gastrointestinal, headache, myalgia, shivering and temperature (defined as oral temperature equal to or above (â‰¥) 38.0 degrees Celsius). Any = incidence of a particular symptom regardless of intensity grade or relationship to vaccination. Grade 3 = general symptom which prevented normal everyday activities. Related = general symptom assessed by the investigator as causally related to the study vaccination. Grade 3 temperature = oral temperature â‰¥39.0Â°C - â‰¤ 40.0Â°C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Any Grade of Solicited General Symptoms.</measure>
    <time_frame>During the 7-day (Days 0-6) post-vaccination period, the second year (2009/2010)</time_frame>
    <description>Solicited general symptoms assessed were arthralgia, fatigue, gastrointestinal, headache, myalgia, shivering and temperature.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Severe (Grade 3) and Related to Vaccination Unsolicited Adverse Events (AEs).</measure>
    <time_frame>Within 21 days (Days 0-20) after the first dose (Year 2008/2009)</time_frame>
    <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Grade 3 = event that prevented normal, everyday activities. Related = event assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Severe (Grade 3) and Related to Vaccination Unsolicited Adverse Events (AEs).</measure>
    <time_frame>Within 21 days (Days 0-20) after the second dose (Year 2009/2010)</time_frame>
    <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Grade 3 = event that prevented normal, everyday activities. Related = event assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Severe (Grade 3) and Related to Vaccination Unsolicited AEs With Medically Attended Visit</measure>
    <time_frame>Within 180 days (Days 0-179) after the first dose (Year 2008/2009)</time_frame>
    <description>For each solicited and unsolicited symptom the subject experienced, the subjects were asked if they received medical attention defined as hospitalisation, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Grade 3 = event that prevented normal everyday activities. Related = event assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Severe (Grade 3) and Related to Vaccination Unsolicited AEs With Medically Attended Visit.</measure>
    <time_frame>Within 180 days (Days 0-179) after the second dose (Year 2009/2010)</time_frame>
    <description>For each solicited and unsolicited symptom the subject experienced, the subjects were asked if they received medical attention defined as hospitalisation, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Grade 3 = event that prevented normal everyday activities. Related = event assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Hemagglutination-inhibition (HI) Antibody Titer Against Each of the 3 Vaccine Influenza Strains.</measure>
    <time_frame>At Days 0 (pre-vaccination Dose 1) and 21 (post-vaccination Dose 1) of the first year (2008/2009) of the study</time_frame>
    <description>Vaccine strains assessed were A/Brisbane/59/2077, A/Uruguay/716/2007 and B/Brisbane/3/2007. Titers were expressed as geometric mean titers calculated on all subjects in the immunogenicity subset of subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Hemagglutination-inhibition (HI) Antibody Titer Against Each of the 3 Vaccine Influenza Strains</measure>
    <time_frame>At Days 0 (pre-vaccination Dose 2) and 21 (post-vaccination Dose 2) of the second year (2009/2010) of the study</time_frame>
    <description>Vaccine strains assessed were A/Brisbane/59/2077, A/Uruguay/716/2007 and B/Brisbane/3/2007. Titers were expressed as geometric mean titers calculated on all subjects in the immunogenicity subset of subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Hemagglutination-inhibition (HI) Antibody Titer Against Each of the 3 Vaccine Influenza Strains.</measure>
    <time_frame>At Days 0 (pre-vaccination Dose 1), 21 (post-vaccination Dose 1) and 180 (post-vaccination Dose 1) of the first year (2008/2009) of the study</time_frame>
    <description>Vaccine strains assessed were A/Brisbane/59/2077, A/Uruguay/716/2007 and B/Brisbane/3/2007. Titers were expressed as geometric mean titers calculated on all subjects for 600 subjects in the persistence subset only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Hemagglutination-inhibition (HI) Antibody Titer Against Each of the 3 Vaccine Influenza Strains.</measure>
    <time_frame>At Days 0 (pre-vaccination Dose 2), 21 (post-vaccination Dose 2) and 180 (post-vaccination Dose 2) of the second year (2009/2010) of the study</time_frame>
    <description>Vaccine strains assessed were A/Brisbane/59/2077, A/Uruguay/716/2007 and B/Brisbane/3/2007. Titers were expressed as geometric mean titers calculated on all subjects for 600 subjects in the persistence subset only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects for HI Antibodies Against Each of the 3 Vaccine Influenza Strains</measure>
    <time_frame>At Day 21 of the first year (2008/2009) of the study.</time_frame>
    <description>In the lot-to-lot subset of subject in the FluGN Group. Vaccine strains assessed were A/Brisbane/59/2077, A/Uruguay/716/2007 and B/Brisbane/3/2007. Seroconversion is defined as the number of subjects with pre-vaccination HI titer (Day 0) &lt; 1:10 and post-vaccination titer (Day 21) â‰¥ 1:40 or a pre-vaccination HI titer (Day 0) â‰¥ 1:10 and fold-increase (post/pre) â‰¥ 4.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43695</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>FluNG Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Bio's influenza vaccine GSK2186877A</intervention_name>
    <description>IM administration, two times one annual dose, 3 different lots will be tested</description>
    <arm_group_label>FluNG Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix TM</intervention_name>
    <description>IM administration, two times one annual dose</description>
    <arm_group_label>Fluarix Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that they can and will comply with the
             requirements of the protocol.

          -  A man or woman aged 65 years or older at the time of the vaccination.

          -  Written informed consent obtained from the subject.

          -  Subjects with residence status allowing free mixing with general community.

        Exclusion Criteria:

          -  Bedridden subjects

          -  Previous vaccination against influenza since February 2008.

          -  Previous vaccination in the last three years with an investigational adjuvanted
             candidate seasonal or pandemic influenza vaccine.

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned
             use during the study period.

          -  Any contra-indication to intramuscular administration of the influenza vaccines.

          -  History of hypersensitivity to a previous dose of influenza vaccine.

          -  History of allergy or reactions likely to be exacerbated by any component of the
             vaccine including egg and chicken protein.

          -  Acute disease at the time of enrolment. Acute disease is defined as the presence of a
             moderate or severe illness with or without fever. All vaccines can be administered to
             persons with a minor illness such as diarrhoea, mild upper respiratory infection with
             or without low-grade febrile illness, i.e. Oral temperature &lt;37.5Â°C (99.5Â°F).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alabaster</city>
        <state>Alabama</state>
        <zip>35007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Crystal River</city>
        <state>Florida</state>
        <zip>34429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33484</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Somers Point</city>
        <state>New Jersey</state>
        <zip>08244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Camillus</city>
        <state>New York</state>
        <zip>13031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Johnson City</city>
        <state>New York</state>
        <zip>13790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tabor City</city>
        <state>North Carolina</state>
        <zip>28463</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Carnegie</city>
        <state>Pennsylvania</state>
        <zip>15106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Grove City</city>
        <state>Pennsylvania</state>
        <zip>16127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jefferson Hills</city>
        <state>Pennsylvania</state>
        <zip>15025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Upper Saint Clair</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29412</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>North Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29582</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>AnthÃ©e</city>
        <zip>5520</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Deinze</city>
        <zip>9800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dour</city>
        <zip>7370</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Drongen</city>
        <zip>9031</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>GozÃ©e</city>
        <zip>6534</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamois (Natoye)</city>
        <zip>5360</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kerksken</city>
        <zip>9451</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Libramont</city>
        <zip>6800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Linkebeek</city>
        <zip>1630</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Maldegem</city>
        <zip>9990</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Melsbroek</city>
        <zip>1820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Merelbeke</city>
        <zip>9820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mettet</city>
        <zip>5640</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oostakker</city>
        <zip>9041</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Waarschoot</city>
        <zip>9950</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coquitlam</city>
        <state>British Columbia</state>
        <zip>V3K 3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bay Roberts</city>
        <state>Newfoundland and Labrador</state>
        <zip>A0A 1G0</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Truro</city>
        <state>Nova Scotia</state>
        <zip>B2N 1L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6T 3T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 1H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8Y 6S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 4J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St-Romulad</city>
        <state>Quebec</state>
        <zip>G6W 5M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 03</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>JaromÄ›Å™</city>
        <zip>551 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>JaromÄ›Å™</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pardubice</city>
        <zip>530 12</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pardubice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saku</city>
        <zip>75501</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10117</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <zip>13619</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tartu</city>
        <zip>50106</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tartu</city>
        <zip>50410</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anzin</city>
        <zip>59410</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Arras</city>
        <zip>62000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>BÃ©con les Granits</city>
        <zip>49370</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cannes</city>
        <zip>06400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chambery</city>
        <zip>73000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>ChÃ¢teau Gontier</city>
        <zip>53200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ecouflant</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gresy sur Aix</city>
        <zip>73100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Rochelle</city>
        <zip>17000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Laval</city>
        <zip>53000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Le Fousseret</city>
        <zip>31430</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreuil Juigne</city>
        <zip>49460</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muret</city>
        <zip>31600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nieul sur Mer</city>
        <zip>17137</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oignies</city>
        <zip>62590</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orthez</city>
        <zip>64300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris Cedex 18</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rosiers d'Egletons</city>
        <zip>19300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>SegrÃ©</city>
        <zip>49500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seysses</city>
        <zip>31600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tierce</city>
        <zip>49125</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tours</city>
        <zip>37100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vourey</city>
        <zip>38210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gueglingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>74363</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68161</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Messkirch</city>
        <state>Baden-Wuerttemberg</state>
        <zip>88605</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rudersberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>73635</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Schwetzingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68723</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sinsheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>74889</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Weinheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Augsburg</city>
        <state>Bayern</state>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haag</city>
        <state>Bayern</state>
        <zip>83527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hoehenkirchen-Siegertsbrunn</city>
        <state>Bayern</state>
        <zip>85635</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kuenzing</city>
        <state>Bayern</state>
        <zip>94550</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80339</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rednitzhembach</city>
        <state>Bayern</state>
        <zip>91126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cottbus</city>
        <state>Brandenburg</state>
        <zip>03050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ketzin</city>
        <state>Brandenburg</state>
        <zip>14669</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ruedersdorf</city>
        <state>Brandenburg</state>
        <zip>15562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bad Kreuznach</city>
        <state>Hessen</state>
        <zip>55545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Floersheim</city>
        <state>Hessen</state>
        <zip>65439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rostock</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Schwerin</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>19055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brinkum/Stuhr</city>
        <state>Niedersachsen</state>
        <zip>28816</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Duelmen</city>
        <state>Niedersachsen</state>
        <zip>48249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koenigslutter</city>
        <state>Niedersachsen</state>
        <zip>38154</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rotenburg (Wuemme)</city>
        <state>Niedersachsen</state>
        <zip>27356</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45359</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Goch</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48155</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Witten</city>
        <state>Nordrhein-Westfalen</state>
        <zip>58455</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ingelheim</city>
        <state>Rheinland-Pfalz</state>
        <zip>55218</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kallstadt</city>
        <state>Rheinland-Pfalz</state>
        <zip>67169</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rhaunen</city>
        <state>Rheinland-Pfalz</state>
        <zip>55624</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koethen</city>
        <state>Sachsen-Anhalt</state>
        <zip>06366</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wolmirstedt</city>
        <state>Sachsen-Anhalt</state>
        <zip>39326</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Borna</city>
        <state>Sachsen</state>
        <zip>04552</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Delitzsch</city>
        <state>Sachsen</state>
        <zip>04509</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Freiberg</city>
        <state>Sachsen</state>
        <zip>09599</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Freital</city>
        <state>Sachsen</state>
        <zip>01705</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Geringswalde</city>
        <state>Sachsen</state>
        <zip>09326</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04207</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04315</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Schmiedeberg</city>
        <state>Sachsen</state>
        <zip>01762</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Weissenberg</city>
        <state>Sachsen</state>
        <zip>02627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bad Bramstedt</city>
        <state>Schleswig-Holstein</state>
        <zip>24576</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bad Segeberg</city>
        <state>Schleswig-Holstein</state>
        <zip>23795</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Luebeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23554</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erfurt</city>
        <state>Thueringen</state>
        <zip>99084</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10365</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10367</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10435</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10629</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10717</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10777</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13086</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20253</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22339</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22769</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ecatepec de Morelos</city>
        <state>Estado de MÃ©xico</state>
        <zip>55075</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cuernavaca</city>
        <state>Morelos</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo LeÃ³n</state>
        <zip>64610</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mexico</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3001 DC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3011 EN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Soest</city>
        <zip>3762 BN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bekkestua</city>
        <zip>1319</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bergen</city>
        <zip>5094</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Elverum</city>
        <zip>2408</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamar</city>
        <zip>2317</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oslo</city>
        <zip>0277</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oslo</city>
        <zip>0484</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Skien</city>
        <zip>3717</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stavanger</city>
        <zip>4005</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-021</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Debica</city>
        <zip>39-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ilawa</city>
        <zip>14-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>InowrocÅ‚aw</city>
        <zip>88-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-018</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>30-695</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-135</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-305</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lubartow</city>
        <zip>21-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Olesnica</city>
        <zip>56-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Plock</city>
        <zip>09-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porabka</city>
        <zip>43-353</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Siemianowice Slaskie</city>
        <zip>41-103</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sopot</city>
        <zip>81-741</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trzebnica</city>
        <zip>55-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tychy</city>
        <zip>43-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-088</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Braila</city>
        <zip>810019</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Braila</city>
        <zip>810384</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brasov</city>
        <zip>500014</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brasov</city>
        <zip>500260</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brasov</city>
        <zip>500366</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>010194</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>020142</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>062289</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>077190</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Craiova</city>
        <zip>200128</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Galati</city>
        <zip>800338</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Galati</city>
        <zip>800578</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pantelimon</city>
        <zip>77145</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ploiesti</city>
        <zip>100172</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barnaul</city>
        <zip>656056</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620137</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Perm</city>
        <zip>614010</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Perm</city>
        <zip>614087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Reading</city>
        <state>Berkshire</state>
        <zip>RG2 0TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buckshaw Village, Chorley</city>
        <state>Lancashire</state>
        <zip>PR7 7NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L22 0LG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Waterloo, Liverpool</city>
        <zip>L22 0LG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2008</study_first_submitted>
  <study_first_submitted_qc>September 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2008</study_first_posted>
  <results_first_submitted>April 26, 2012</results_first_submitted>
  <results_first_submitted_qc>May 17, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 19, 2012</results_first_posted>
  <disposition_first_submitted>July 2, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>July 2, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 7, 2010</disposition_first_posted>
  <last_update_submitted>August 23, 2017</last_update_submitted>
  <last_update_submitted_qc>August 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Efficacy</keyword>
  <keyword>Influenza Vaccines</keyword>
  <keyword>Influenza</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>106372</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>106372</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>106372</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>106372</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>106372</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>106372</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>106372</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were vaccinated during the pre-influenza season at Day 0, were contacted by phone during the surveillance period from mid November to the end of the influenza season (April-May) and were contacted by phone at Days 270 and 365 for the Year 1 influenza season 2008/2009 and the Year 2 influenza season 2009/2010.</recruitment_details>
      <pre_assignment_details>For lot-to-lot consistency analyses after Dose 1 at Day 0 of the Year 1, FluNG Group was divided in 3 sub-groups: FluNG Lot 1 Group, FluNG Lot 2 Group and FluNG Lot 3 Group: subjects received 1 dose of FluNG vaccine Lot 1, 2 or 3 at Day 0 of the Year 1. They all received Dose 2 at Day 0 of the Year 2, again from 3 different lots.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FluNG Group</title>
          <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
        </group>
        <group group_id="P2">
          <title>Fluarix Group</title>
          <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21893"/>
                <participants group_id="P2" count="21802"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16911"/>
                <participants group_id="P2" count="16895"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4982"/>
                <participants group_id="P2" count="4907"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="878"/>
                <participants group_id="P2" count="869"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2481"/>
                <participants group_id="P2" count="2407"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="491"/>
                <participants group_id="P2" count="497"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1104"/>
                <participants group_id="P2" count="1088"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FluNG Group</title>
          <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
        </group>
        <group group_id="B2">
          <title>Fluarix Group</title>
          <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21893"/>
            <count group_id="B2" value="21802"/>
            <count group_id="B3" value="43695"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.5" spread="6.09"/>
                    <measurement group_id="B2" value="73.5" spread="6.16"/>
                    <measurement group_id="B3" value="73.5" spread="6.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12549"/>
                    <measurement group_id="B2" value="12422"/>
                    <measurement group_id="B3" value="24971"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9344"/>
                    <measurement group_id="B2" value="9380"/>
                    <measurement group_id="B3" value="18724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Polymerase Chain Reaction (PCR)-Confirmed Influenza A and/or B Infection.</title>
        <description>Occurrence of PCR-confirmed influenza A and/or B infection, due to any matching or drift influenza strain relative to the vaccine strains (i.e. not emerging novel human influenza strain like H1N1v). PCR-confirmed influenza (PCI) was defined as an episode of influenza-like illness (ILI) occurring after the administration of the study vaccine for which a nasal and throat swab specimen yields influenza virus A and/or B by reverse transcription polymerase chain reaction (RT-PCR) analysis.</description>
        <time_frame>After the first dose during the corresponding surveillance period (from mid November 2008 to the end of April 2009 (end of influenza season))</time_frame>
        <population>The One-Dose According-To-Protocol cohort for efficacy included eligible subjects from the One-Dose Total Vaccinated cohort (e.g. who complied with the protocol, with no elimination criteria assigned during the study), who had started their first surveillance period, who had not received a seasonal influenza vaccine not foreseen in the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Group</title>
            <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Polymerase Chain Reaction (PCR)-Confirmed Influenza A and/or B Infection.</title>
          <description>Occurrence of PCR-confirmed influenza A and/or B infection, due to any matching or drift influenza strain relative to the vaccine strains (i.e. not emerging novel human influenza strain like H1N1v). PCR-confirmed influenza (PCI) was defined as an episode of influenza-like illness (ILI) occurring after the administration of the study vaccine for which a nasal and throat swab specimen yields influenza virus A and/or B by reverse transcription polymerase chain reaction (RT-PCR) analysis.</description>
          <population>The One-Dose According-To-Protocol cohort for efficacy included eligible subjects from the One-Dose Total Vaccinated cohort (e.g. who complied with the protocol, with no elimination criteria assigned during the study), who had started their first surveillance period, who had not received a seasonal influenza vaccine not foreseen in the protocol.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21573"/>
                <count group_id="O2" value="21482"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274"/>
                    <measurement group_id="O2" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Hemagglutination-inhibition (HI) Antibody Titers, Against Each of the 3 Vaccine Influenza Strains, in the FluNG Groups.</title>
        <description>Vaccine strains assessed were A/Brisbane/59/2077, A/Uruguay/716/2007 and B/Brisbane/3/2007. Titers were expressed as geometric mean titers calculated on all subjects in the lot-to-lot subset of subjects.</description>
        <time_frame>At Days 0 (pre-vaccination Dose 1) and 21 (post-vaccination Dose 1) of the first year (2008/2009) of the study</time_frame>
        <population>The One-Dose According-To-Protocol immunogenicity cohort for the lot-to-lot consistency subset included all subjects from the One-Dose ATP cohort for immunogenicity included in the lot-to-lot subset.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Group</title>
            <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O3">
            <title>FluNG Lot 1 Group</title>
            <description>subjects received 1 dose of FluNG vaccine Lot 1 at Day 0 of the Year 1. They received Dose 2 at Day 0 of the Year 2, again from lot 1. The vaccine was administered intramuscularly in the non-dominant deltoid.</description>
          </group>
          <group group_id="O4">
            <title>FluNG Lot 2 Group</title>
            <description>subjects received 1 dose of FluNG vaccine Lot 2 at Day 0 of the Year 1. They received Dose 2 at Day 0 of the Year 2, again from lot 2. The vaccine was administered intramuscularly in the non-dominant deltoid.</description>
          </group>
          <group group_id="O5">
            <title>FluNG Lot 3 Group</title>
            <description>subjects received 1 dose of FluNG vaccine Lot 3 at Day 0 of the Year 1. They received Dose 2 at Day 0 of the Year 2, again from lot 3. The vaccine was administered intramuscularly in the non-dominant deltoid.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Hemagglutination-inhibition (HI) Antibody Titers, Against Each of the 3 Vaccine Influenza Strains, in the FluNG Groups.</title>
          <description>Vaccine strains assessed were A/Brisbane/59/2077, A/Uruguay/716/2007 and B/Brisbane/3/2007. Titers were expressed as geometric mean titers calculated on all subjects in the lot-to-lot subset of subjects.</description>
          <population>The One-Dose According-To-Protocol immunogenicity cohort for the lot-to-lot consistency subset included all subjects from the One-Dose ATP cohort for immunogenicity included in the lot-to-lot subset.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="540"/>
                <count group_id="O4" value="538"/>
                <count group_id="O5" value="534"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane [Day 0] (N=539,536,532)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="15.9" lower_limit="14.6" upper_limit="17.3"/>
                    <measurement group_id="O4" value="15.8" lower_limit="14.5" upper_limit="17.2"/>
                    <measurement group_id="O5" value="15.8" lower_limit="14.5" upper_limit="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [Day 21] (N=540,538,534)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="82.3" lower_limit="75.0" upper_limit="90.2"/>
                    <measurement group_id="O4" value="83.6" lower_limit="76.0" upper_limit="92.0"/>
                    <measurement group_id="O5" value="93.4" lower_limit="84.6" upper_limit="103.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [Day 0] (N=539,536,532)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="18.2" lower_limit="16.5" upper_limit="20.2"/>
                    <measurement group_id="O4" value="17.8" lower_limit="16.0" upper_limit="19.9"/>
                    <measurement group_id="O5" value="17.3" lower_limit="15.6" upper_limit="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [Day 21] (N=540,538,534)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="272.5" lower_limit="243.0" upper_limit="305.6"/>
                    <measurement group_id="O4" value="287.5" lower_limit="256.2" upper_limit="322.7"/>
                    <measurement group_id="O5" value="269.9" lower_limit="239.9" upper_limit="303.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane[Day 0] (N=539,536,532)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="94.2" lower_limit="84.8" upper_limit="104.7"/>
                    <measurement group_id="O4" value="89.9" lower_limit="80.6" upper_limit="100.3"/>
                    <measurement group_id="O5" value="87.1" lower_limit="78.3" upper_limit="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane[Day 21] (N=540,538,534)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="652.4" lower_limit="602.0" upper_limit="707.1"/>
                    <measurement group_id="O4" value="596.9" lower_limit="552.2" upper_limit="645.3"/>
                    <measurement group_id="O5" value="601.7" lower_limit="555.0" upper_limit="652.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Polymerase Chain Reaction (PCR)-Confirmed Influenza A and/or B Infection.</title>
        <description>Occurrence of PCR-confirmed influenza A and/or B infection, due to any matching or drift influenza strain relative to the vaccine strains (i.e. not emerging novel human influenza strain like H1N1v). PCR-confirmed influenza (PCI) was defined as an episode of influenza-like illness (ILI) occurring after the administration of the study vaccine for which a nasal and throat swab specimen yields influenza virus A and/or B by reverse transcription polymerase chain reaction (RT-PCR) analysis.</description>
        <time_frame>During the whole surveillance period (from mid November 2008 to end of April 2009 and from mid November 2009 to end of April 2010)</time_frame>
        <population>The According-To-Protocol cohort for efficacy included all eligible subjects from the Total Vaccinated cohort (e.g. who complied with the protocol, with no elimination criteria assigned during the study), who had started their first surveillance period, who had not received a seasonal influenza vaccine not foreseen in the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Group</title>
            <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Polymerase Chain Reaction (PCR)-Confirmed Influenza A and/or B Infection.</title>
          <description>Occurrence of PCR-confirmed influenza A and/or B infection, due to any matching or drift influenza strain relative to the vaccine strains (i.e. not emerging novel human influenza strain like H1N1v). PCR-confirmed influenza (PCI) was defined as an episode of influenza-like illness (ILI) occurring after the administration of the study vaccine for which a nasal and throat swab specimen yields influenza virus A and/or B by reverse transcription polymerase chain reaction (RT-PCR) analysis.</description>
          <population>The According-To-Protocol cohort for efficacy included all eligible subjects from the Total Vaccinated cohort (e.g. who complied with the protocol, with no elimination criteria assigned during the study), who had started their first surveillance period, who had not received a seasonal influenza vaccine not foreseen in the protocol.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20579"/>
                <count group_id="O2" value="20458"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="262"/>
                    <measurement group_id="O2" value="296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Culture-confirmed Influenza A and/or B Infection.</title>
        <description>Occurrence of culture-confirmed influenza A and/or B infection, due to any matching or drift influenza strain relative to the vaccine strains (i.e. not emerging novel human influenza strain like H1N1v). Culture-confirmed influenza (CCI) was defined as an episode of ILI occurring after the administration of the study vaccine for which a nasal and throat swab specimen yields influenza virus A and/or B by viral culture analysis.</description>
        <time_frame>During the whole surveillance period (from mid November 2008 to end of April 2009 and from mid November 2009 to end of April 2010)</time_frame>
        <population>The According-To-Protocol cohort for efficacy included all eligible subjects from the Total Vaccinated cohort (e.g. who complied with the protocol, with no elimination criteria assigned during the study), who had started their first surveillance period, who had not received a seasonal influenza vaccine not foreseen in the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Group</title>
            <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Culture-confirmed Influenza A and/or B Infection.</title>
          <description>Occurrence of culture-confirmed influenza A and/or B infection, due to any matching or drift influenza strain relative to the vaccine strains (i.e. not emerging novel human influenza strain like H1N1v). Culture-confirmed influenza (CCI) was defined as an episode of ILI occurring after the administration of the study vaccine for which a nasal and throat swab specimen yields influenza virus A and/or B by viral culture analysis.</description>
          <population>The According-To-Protocol cohort for efficacy included all eligible subjects from the Total Vaccinated cohort (e.g. who complied with the protocol, with no elimination criteria assigned during the study), who had started their first surveillance period, who had not received a seasonal influenza vaccine not foreseen in the protocol.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20579"/>
                <count group_id="O2" value="20458"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                    <measurement group_id="O2" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Pneumonia or Clinical Influenza After the First Dose of Vaccine.</title>
        <description>Clinical influenza= An ILI episode (with an ILI onset from the 15th of November until the end of the surveillance period) with at least simultaneously fever (oral temperature of â‰¥37.8 degrees Celsius) and cough.
The influenza peak season = period during the study with the highest incidence of any matching or drift influenza strain relative to the vaccine strains (i.e. not emerging novel human influenza strain like H1N1v).</description>
        <time_frame>During the influenza peak season within the first surveillance period (the influenza peak season being defined per country, falling somewhere between mid November 2008 to end of April 2009)</time_frame>
        <population>The One-Dose According-To-Protocol cohort for efficacy for peak season included all subjects from the One-Dose ATP cohort for efficacy who did not drop out from the study before the start of their first influenza peak season.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Group</title>
            <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Pneumonia or Clinical Influenza After the First Dose of Vaccine.</title>
          <description>Clinical influenza= An ILI episode (with an ILI onset from the 15th of November until the end of the surveillance period) with at least simultaneously fever (oral temperature of â‰¥37.8 degrees Celsius) and cough.
The influenza peak season = period during the study with the highest incidence of any matching or drift influenza strain relative to the vaccine strains (i.e. not emerging novel human influenza strain like H1N1v).</description>
          <population>The One-Dose According-To-Protocol cohort for efficacy for peak season included all subjects from the One-Dose ATP cohort for efficacy who did not drop out from the study before the start of their first influenza peak season.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21394"/>
                <count group_id="O2" value="21337"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202"/>
                    <measurement group_id="O2" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting All-cause Death After the First Dose of Vaccine.</title>
        <description>The influenza peak season = period during the study with the highest incidence of any matching or drift influenza strain relative to the vaccine strains (i.e. not emerging novel human influenza strain like H1N1v).</description>
        <time_frame>During the influenza peak season within the first surveillance period (the influenza peak season being defined per country, falling somewhere between mid November 2008 to end of April 2009)</time_frame>
        <population>The One-Dose According-To-Protocol cohort for efficacy for peak season included all subjects from the One-Dose ATP cohort for efficacy who did not drop out from the study before the start of their first influenza peak season.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Group</title>
            <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting All-cause Death After the First Dose of Vaccine.</title>
          <description>The influenza peak season = period during the study with the highest incidence of any matching or drift influenza strain relative to the vaccine strains (i.e. not emerging novel human influenza strain like H1N1v).</description>
          <population>The One-Dose According-To-Protocol cohort for efficacy for peak season included all subjects from the One-Dose ATP cohort for efficacy who did not drop out from the study before the start of their first influenza peak season.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21394"/>
                <count group_id="O2" value="21337"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Hospitalization Due to Respiratory Diseases After the First Dose of Vaccine</title>
        <description>Respiratory disease: A diagnosis of respiratory disease included: acute respiratory infections, other diseases of upper respiratory tract, pneumonia and influenza, chronic obstructive pulmonary disease and allied conditions, pneumoconioses and other lung diseases due to external agents, other diseases of respiratory system. In case the event has a fatal outcome, the diagnosis can also be confirmed by autopsy.</description>
        <time_frame>During the influenza peak season within the first surveillance period (the influenza peak season being defined per country, falling somewhere between mid November 2008 to end of April 2009)</time_frame>
        <population>The One-Dose According-To-Protocol cohort for efficacy for peak season included all subjects from the One-Dose ATP cohort for efficacy who did not drop out from the study before the start of their first influenza peak season.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Group</title>
            <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Hospitalization Due to Respiratory Diseases After the First Dose of Vaccine</title>
          <description>Respiratory disease: A diagnosis of respiratory disease included: acute respiratory infections, other diseases of upper respiratory tract, pneumonia and influenza, chronic obstructive pulmonary disease and allied conditions, pneumoconioses and other lung diseases due to external agents, other diseases of respiratory system. In case the event has a fatal outcome, the diagnosis can also be confirmed by autopsy.</description>
          <population>The One-Dose According-To-Protocol cohort for efficacy for peak season included all subjects from the One-Dose ATP cohort for efficacy who did not drop out from the study before the start of their first influenza peak season.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21394"/>
                <count group_id="O2" value="21337"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Severe (Grade 3) and Related to Vaccination Adverse Events (AEs) of Specific Interest Including Autoimmune Disease (AID).</title>
        <description>Adverse events of specific interest for safety monitoring are a subset of AEs that included both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.
Grade 3 = event that prevented normal everyday activities Related = event assessed by the investigator as causally related to the study vaccination</description>
        <time_frame>Within 365 days after the first dose (from Dose 1 at Day 0 up to Day 365 for the Year 2008/2009)</time_frame>
        <population>The One-Dose Total Vaccinated cohort included all subjects with one vaccine administration documented during the first year of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Group</title>
            <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Severe (Grade 3) and Related to Vaccination Adverse Events (AEs) of Specific Interest Including Autoimmune Disease (AID).</title>
          <description>Adverse events of specific interest for safety monitoring are a subset of AEs that included both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.
Grade 3 = event that prevented normal everyday activities Related = event assessed by the investigator as causally related to the study vaccination</description>
          <population>The One-Dose Total Vaccinated cohort included all subjects with one vaccine administration documented during the first year of the study.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21893"/>
                <count group_id="O2" value="21802"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Severe (Grade 3) and Related to Vaccination Adverse Events (AEs) of Specific Interest Including Autoimmune Disease (AID).</title>
        <description>Adverse events of specific interest for safety monitoring are a subset of AEs that included both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.
Grade 3 = event that prevented normal everyday activities Related = event assessed by the investigator as causally related to the study vaccination</description>
        <time_frame>Within 365 days after the second dose (from Dose 1 at Day 0 up to Day 365 for the Year 2009/2010)</time_frame>
        <population>The Two-Dose Total Vaccinated cohort included all subjects with one vaccine administration documented in each year of the study</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Group</title>
            <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Severe (Grade 3) and Related to Vaccination Adverse Events (AEs) of Specific Interest Including Autoimmune Disease (AID).</title>
          <description>Adverse events of specific interest for safety monitoring are a subset of AEs that included both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.
Grade 3 = event that prevented normal everyday activities Related = event assessed by the investigator as causally related to the study vaccination</description>
          <population>The Two-Dose Total Vaccinated cohort included all subjects with one vaccine administration documented in each year of the study</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17070"/>
                <count group_id="O2" value="17071"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Severe (Grade 3) and Related to Vaccination Adverse Events (AEs) of Specific Interest Including Autoimmune Disease (AID).</title>
        <description>Adverse events of specific interest for safety monitoring are a subset of AEs that included both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.
Grade 3 = event that prevented normal everyday activities Related = event assessed by the investigator as causally related to the study vaccination</description>
        <time_frame>During the entire study period (during the 365 days of follow-up after each vaccination at Year 2008/2009 and Year 2009/2010)</time_frame>
        <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Group</title>
            <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Severe (Grade 3) and Related to Vaccination Adverse Events (AEs) of Specific Interest Including Autoimmune Disease (AID).</title>
          <description>Adverse events of specific interest for safety monitoring are a subset of AEs that included both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.
Grade 3 = event that prevented normal everyday activities Related = event assessed by the investigator as causally related to the study vaccination</description>
          <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21893"/>
                <count group_id="O2" value="21802"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Related to Vaccination Serious Adverse Events (SAEs).</title>
        <description>SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.
Related = event assessed by the investigator as causally related to the study vaccination</description>
        <time_frame>During the entire study period (during the 365 days of follow-up after each vaccination at Year 2008/2009 and Year 2009/2010)</time_frame>
        <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Group</title>
            <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Related to Vaccination Serious Adverse Events (SAEs).</title>
          <description>SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.
Related = event assessed by the investigator as causally related to the study vaccination</description>
          <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21893"/>
                <count group_id="O2" value="21802"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4071"/>
                    <measurement group_id="O2" value="4066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Severe (Grade 3) Solicited Local Symptoms.</title>
        <description>Solicited local symptoms assessed were ecchymosis, pain, redness and swelling. Any = incidence of a particular symptom regardless of intensity grade. Grade 3 pain = considerable pain at rest that prevented normal everyday activities. Grade 3 ecchymosis/redness/swelling = ecchymosis/redness/swelling above 100 millimeter</description>
        <time_frame>During the 7-day (Days 0-6) post-vaccination period, the first year (2008/2009)</time_frame>
        <population>The One-Dose Total Vaccinated cohort for the safety subset included all subjects with at least one vaccine administration documented during the first year of the study and included in the safety subset.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Group</title>
            <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Severe (Grade 3) Solicited Local Symptoms.</title>
          <description>Solicited local symptoms assessed were ecchymosis, pain, redness and swelling. Any = incidence of a particular symptom regardless of intensity grade. Grade 3 pain = considerable pain at rest that prevented normal everyday activities. Grade 3 ecchymosis/redness/swelling = ecchymosis/redness/swelling above 100 millimeter</description>
          <population>The One-Dose Total Vaccinated cohort for the safety subset included all subjects with at least one vaccine administration documented during the first year of the study and included in the safety subset.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2988"/>
                <count group_id="O2" value="2968"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis &gt; 100 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1225"/>
                    <measurement group_id="O2" value="477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness &gt; 100 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling &gt; 100 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Any Grade of Solicited Local Symptoms</title>
        <description>Solicited local symptoms assessed were ecchymosis, pain, redness and swelling</description>
        <time_frame>During the 7-day (Days 0-6) post-vaccination period, the first year (2008/2009)</time_frame>
        <population>The One-Dose Total Vaccinated cohort for the safety subset included all subjects with at least one vaccine administration documented during the first year of the study and included in the safety subset.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Group</title>
            <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With Any Grade of Solicited Local Symptoms</title>
          <description>Solicited local symptoms assessed were ecchymosis, pain, redness and swelling</description>
          <population>The One-Dose Total Vaccinated cohort for the safety subset included all subjects with at least one vaccine administration documented during the first year of the study and included in the safety subset.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1221"/>
                <count group_id="O2" value="476"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ecchymosis (N=39,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (N=1221,476)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.1" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness (N=237,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.5" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (N=186,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Severe (Grade 3) Solicited Local Symptoms</title>
        <description>Solicited local symptoms assessed were ecchymosis, pain, redness and swelling. Any = incidence of a particular symptom regardless of intensity grade. Grade 3 pain = considerable pain at rest that prevented normal everyday activities. Grade 3 ecchymosis/redness/swelling = ecchymosis/redness/swelling above 100 millimeter</description>
        <time_frame>During the 7-day (Days 0-6) post-vaccination period, the second year (2009/2010)</time_frame>
        <population>The Two-Dose Total Vaccinated cohort for the safety subset included all subjects with at least one vaccine administration documented in each year of the study and included in the safety subset.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Group</title>
            <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Severe (Grade 3) Solicited Local Symptoms</title>
          <description>Solicited local symptoms assessed were ecchymosis, pain, redness and swelling. Any = incidence of a particular symptom regardless of intensity grade. Grade 3 pain = considerable pain at rest that prevented normal everyday activities. Grade 3 ecchymosis/redness/swelling = ecchymosis/redness/swelling above 100 millimeter</description>
          <population>The Two-Dose Total Vaccinated cohort for the safety subset included all subjects with at least one vaccine administration documented in each year of the study and included in the safety subset.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2441"/>
                <count group_id="O2" value="2488"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis &gt; 100 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="998"/>
                    <measurement group_id="O2" value="440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness &gt; 100 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling &gt; 100 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Any Grade of Solicited Local Symptoms.</title>
        <description>Solicited local symptoms assessed were ecchymosis, pain, redness and swelling.</description>
        <time_frame>During the 7-day (Days 0-6) post-vaccination period, the second year (2009/2010)</time_frame>
        <population>The Two-Dose Total Vaccinated cohort for the safety subset included all subjects with at least one vaccine administration documented in each year of the study and included in the safety subset.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Group</title>
            <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With Any Grade of Solicited Local Symptoms.</title>
          <description>Solicited local symptoms assessed were ecchymosis, pain, redness and swelling.</description>
          <population>The Two-Dose Total Vaccinated cohort for the safety subset included all subjects with at least one vaccine administration documented in each year of the study and included in the safety subset.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="995"/>
                <count group_id="O2" value="431"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ecchymosis (N=28,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="3.6" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (N=995,431)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness (N=202,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.6" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (N=162,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.7" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Severe (Grade 3) and Related to Vaccination Solicited General Symptoms</title>
        <description>Solicited general symptoms assessed were arthralgia, fatigue, gastrointestinal, headache, myalgia, shivering and temperature (defined as oral temperature equal to or above (â‰¥) 38.0 degrees Celsius). Any = incidence of a particular symptom regardless of intensity grade or relationship to vaccination. Grade 3 = general symptom which prevented normal everyday activities. Related = general symptom assessed by the investigator as causally related to the study vaccination. Grade 3 temperature = oral temperature â‰¥39.0Â°C - â‰¤ 40.0Â°C.</description>
        <time_frame>During the 7-day (Days 0-6) post-vaccination period, the first year (2008/2009)</time_frame>
        <population>The One-Dose Total Vaccinated cohort for the safety subset included all subjects with at least one vaccine administration documented during the first year of the study and included in the safety subset.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Group</title>
            <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Severe (Grade 3) and Related to Vaccination Solicited General Symptoms</title>
          <description>Solicited general symptoms assessed were arthralgia, fatigue, gastrointestinal, headache, myalgia, shivering and temperature (defined as oral temperature equal to or above (â‰¥) 38.0 degrees Celsius). Any = incidence of a particular symptom regardless of intensity grade or relationship to vaccination. Grade 3 = general symptom which prevented normal everyday activities. Related = general symptom assessed by the investigator as causally related to the study vaccination. Grade 3 temperature = oral temperature â‰¥39.0Â°C - â‰¤ 40.0Â°C.</description>
          <population>The One-Dose Total Vaccinated cohort for the safety subset included all subjects with at least one vaccine administration documented during the first year of the study and included in the safety subset.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2986"/>
                <count group_id="O2" value="2968"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="391"/>
                    <measurement group_id="O2" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="285"/>
                    <measurement group_id="O2" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="646"/>
                    <measurement group_id="O2" value="417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="494"/>
                    <measurement group_id="O2" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197"/>
                    <measurement group_id="O2" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="474"/>
                    <measurement group_id="O2" value="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="341"/>
                    <measurement group_id="O2" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="547"/>
                    <measurement group_id="O2" value="302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="412"/>
                    <measurement group_id="O2" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature &gt;= 38.0Â°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature &gt;= 39.0Â°C - &lt;=40.0Â°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Any Grade of Solicited General Symptoms</title>
        <description>Solicited general symptoms assessed were arthralgia, fatigue, gastrointestinal, headache, myalgia, shivering and temperature.</description>
        <time_frame>During the 7-day (Days 0-6) post-vaccination period, the first year (2008/2009)</time_frame>
        <population>The One-Dose Total Vaccinated cohort for the safety subset included all subjects with at least one vaccine administration documented during the first year of the study and included in the safety subset.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Group</title>
            <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With Any Grade of Solicited General Symptoms</title>
          <description>Solicited general symptoms assessed were arthralgia, fatigue, gastrointestinal, headache, myalgia, shivering and temperature.</description>
          <population>The One-Dose Total Vaccinated cohort for the safety subset included all subjects with at least one vaccine administration documented during the first year of the study and included in the safety subset.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="642"/>
                <count group_id="O2" value="417"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Arthralgia (N=388,239)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.9" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (N=642,417)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.7" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal (N=195,164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.2" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N=472,332)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.3" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N=544,301)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.3" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering (N=244,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.1" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature (N=59,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="1.3" lower_limit="1.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms.</title>
        <description>Solicited general symptoms assessed were arthralgia, fatigue, gastrointestinal, headache, myalgia, shivering and temperature (defined as oral temperature equal to or above (â‰¥) 38.0 degrees Celsius). Any = incidence of a particular symptom regardless of intensity grade or relationship to vaccination. Grade 3 = general symptom which prevented normal everyday activities. Related = general symptom assessed by the investigator as causally related to the study vaccination. Grade 3 temperature = oral temperature â‰¥39.0Â°C - â‰¤ 40.0Â°C.</description>
        <time_frame>During the 7-day (Days 0-6) post-vaccination period, the second year (2009/2010)</time_frame>
        <population>The Two-Dose Total Vaccinated cohort for the safety subset included all subjects with at least one vaccine administration documented in each year of the study and included in the safety subset.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Group</title>
            <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Severe (Grade 3) and Related Solicited General Symptoms.</title>
          <description>Solicited general symptoms assessed were arthralgia, fatigue, gastrointestinal, headache, myalgia, shivering and temperature (defined as oral temperature equal to or above (â‰¥) 38.0 degrees Celsius). Any = incidence of a particular symptom regardless of intensity grade or relationship to vaccination. Grade 3 = general symptom which prevented normal everyday activities. Related = general symptom assessed by the investigator as causally related to the study vaccination. Grade 3 temperature = oral temperature â‰¥39.0Â°C - â‰¤ 40.0Â°C.</description>
          <population>The Two-Dose Total Vaccinated cohort for the safety subset included all subjects with at least one vaccine administration documented in each year of the study and included in the safety subset.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2436"/>
                <count group_id="O2" value="2489"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="258"/>
                    <measurement group_id="O2" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="457"/>
                    <measurement group_id="O2" value="318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="307"/>
                    <measurement group_id="O2" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="342"/>
                    <measurement group_id="O2" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="380"/>
                    <measurement group_id="O2" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261"/>
                    <measurement group_id="O2" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature &gt;= 38.0Â°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature &gt;= 39.0Â°C - &lt;= 40.0Â°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Any Grade of Solicited General Symptoms.</title>
        <description>Solicited general symptoms assessed were arthralgia, fatigue, gastrointestinal, headache, myalgia, shivering and temperature.</description>
        <time_frame>During the 7-day (Days 0-6) post-vaccination period, the second year (2009/2010)</time_frame>
        <population>The Two-Dose Total Vaccinated cohort for the safety subset included all subjects with at least one vaccine administration documented in each year of the study and included in the safety subset.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Group</title>
            <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With Any Grade of Solicited General Symptoms.</title>
          <description>Solicited general symptoms assessed were arthralgia, fatigue, gastrointestinal, headache, myalgia, shivering and temperature.</description>
          <population>The Two-Dose Total Vaccinated cohort for the safety subset included all subjects with at least one vaccine administration documented in each year of the study and included in the safety subset.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="446"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Arthralgia (N=247,169)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (N=446,313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.7" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal (N=125,115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.6" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N=331,229)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.4" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N=370,200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.6" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering (N=177,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.3" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature (N=38,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Severe (Grade 3) and Related to Vaccination Unsolicited Adverse Events (AEs).</title>
        <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Grade 3 = event that prevented normal, everyday activities. Related = event assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Within 21 days (Days 0-20) after the first dose (Year 2008/2009)</time_frame>
        <population>The One-Dose Total Vaccinated cohort for the safety subset included all subjects with at least one vaccine administration documented during the first year of the study and included in the safety subset.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Group</title>
            <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Severe (Grade 3) and Related to Vaccination Unsolicited Adverse Events (AEs).</title>
          <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Grade 3 = event that prevented normal, everyday activities. Related = event assessed by the investigator as causally related to the study vaccination.</description>
          <population>The One-Dose Total Vaccinated cohort for the safety subset included all subjects with at least one vaccine administration documented during the first year of the study and included in the safety subset.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3015"/>
                <count group_id="O2" value="3002"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="428"/>
                    <measurement group_id="O2" value="427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Severe (Grade 3) and Related to Vaccination Unsolicited Adverse Events (AEs).</title>
        <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Grade 3 = event that prevented normal, everyday activities. Related = event assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Within 21 days (Days 0-20) after the second dose (Year 2009/2010)</time_frame>
        <population>The Two-Dose Total Vaccinated cohort for the safety subset included all subjects with at least one vaccine administration documented in each year of the study and included in the safety subset.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Group</title>
            <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Severe (Grade 3) and Related to Vaccination Unsolicited Adverse Events (AEs).</title>
          <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Grade 3 = event that prevented normal, everyday activities. Related = event assessed by the investigator as causally related to the study vaccination.</description>
          <population>The Two-Dose Total Vaccinated cohort for the safety subset included all subjects with at least one vaccine administration documented in each year of the study and included in the safety subset.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2462"/>
                <count group_id="O2" value="2520"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="320"/>
                    <measurement group_id="O2" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Severe (Grade 3) and Related to Vaccination Unsolicited AEs With Medically Attended Visit</title>
        <description>For each solicited and unsolicited symptom the subject experienced, the subjects were asked if they received medical attention defined as hospitalisation, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Grade 3 = event that prevented normal everyday activities. Related = event assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Within 180 days (Days 0-179) after the first dose (Year 2008/2009)</time_frame>
        <population>The One-Dose Total Vaccinated cohort for the safety subset included all subjects with at least one vaccine administration documented during the first year of the study and included in the safety subset.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Group</title>
            <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Severe (Grade 3) and Related to Vaccination Unsolicited AEs With Medically Attended Visit</title>
          <description>For each solicited and unsolicited symptom the subject experienced, the subjects were asked if they received medical attention defined as hospitalisation, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Grade 3 = event that prevented normal everyday activities. Related = event assessed by the investigator as causally related to the study vaccination.</description>
          <population>The One-Dose Total Vaccinated cohort for the safety subset included all subjects with at least one vaccine administration documented during the first year of the study and included in the safety subset.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3015"/>
                <count group_id="O2" value="3002"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1018"/>
                    <measurement group_id="O2" value="996"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223"/>
                    <measurement group_id="O2" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Severe (Grade 3) and Related to Vaccination Unsolicited AEs With Medically Attended Visit.</title>
        <description>For each solicited and unsolicited symptom the subject experienced, the subjects were asked if they received medical attention defined as hospitalisation, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Grade 3 = event that prevented normal everyday activities. Related = event assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Within 180 days (Days 0-179) after the second dose (Year 2009/2010)</time_frame>
        <population>The Two-Dose Total Vaccinated cohort for the safety subset included all subjects with at least one vaccine administration documented in each year of the study and included in the safety subset.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Group</title>
            <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Severe (Grade 3) and Related to Vaccination Unsolicited AEs With Medically Attended Visit.</title>
          <description>For each solicited and unsolicited symptom the subject experienced, the subjects were asked if they received medical attention defined as hospitalisation, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Grade 3 = event that prevented normal everyday activities. Related = event assessed by the investigator as causally related to the study vaccination.</description>
          <population>The Two-Dose Total Vaccinated cohort for the safety subset included all subjects with at least one vaccine administration documented in each year of the study and included in the safety subset.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2462"/>
                <count group_id="O2" value="2520"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="849"/>
                    <measurement group_id="O2" value="864"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Hemagglutination-inhibition (HI) Antibody Titer Against Each of the 3 Vaccine Influenza Strains.</title>
        <description>Vaccine strains assessed were A/Brisbane/59/2077, A/Uruguay/716/2007 and B/Brisbane/3/2007. Titers were expressed as geometric mean titers calculated on all subjects in the immunogenicity subset of subjects.</description>
        <time_frame>At Days 0 (pre-vaccination Dose 1) and 21 (post-vaccination Dose 1) of the first year (2008/2009) of the study</time_frame>
        <population>The One-Dose According-To-Protocol cohort for immunogenicity included evaluable subjects for whom data concerning immunogenicity outcome measures were available in terms of antibodies against at least one study vaccine antigen component at Day 21 of the first year of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Group</title>
            <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Hemagglutination-inhibition (HI) Antibody Titer Against Each of the 3 Vaccine Influenza Strains.</title>
          <description>Vaccine strains assessed were A/Brisbane/59/2077, A/Uruguay/716/2007 and B/Brisbane/3/2007. Titers were expressed as geometric mean titers calculated on all subjects in the immunogenicity subset of subjects.</description>
          <population>The One-Dose According-To-Protocol cohort for immunogenicity included evaluable subjects for whom data concerning immunogenicity outcome measures were available in terms of antibodies against at least one study vaccine antigen component at Day 21 of the first year of the study.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2422"/>
                <count group_id="O2" value="2408"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane [Day 0] (N=2417,2397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" lower_limit="14.9" upper_limit="16.1"/>
                    <measurement group_id="O2" value="15.3" lower_limit="14.7" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [Day 21] (N=2422,2408)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.1" lower_limit="85.2" upper_limit="93.2"/>
                    <measurement group_id="O2" value="69.9" lower_limit="66.5" upper_limit="73.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [Day 0] (N=2417,2397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="16.6" upper_limit="18.3"/>
                    <measurement group_id="O2" value="17.4" lower_limit="16.5" upper_limit="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [Day 21] (N=2422,2408)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="285.6" lower_limit="270.6" upper_limit="301.4"/>
                    <measurement group_id="O2" value="172.3" lower_limit="162.7" upper_limit="182.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [Day 0] (N=2416,2397)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.3" lower_limit="81.2" upper_limit="89.7"/>
                    <measurement group_id="O2" value="82.4" lower_limit="78.3" upper_limit="86.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [Day 21] (N=2422,2408)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="633.5" lower_limit="609.9" upper_limit="658.0"/>
                    <measurement group_id="O2" value="484.8" lower_limit="465.1" upper_limit="505.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Hemagglutination-inhibition (HI) Antibody Titer Against Each of the 3 Vaccine Influenza Strains</title>
        <description>Vaccine strains assessed were A/Brisbane/59/2077, A/Uruguay/716/2007 and B/Brisbane/3/2007. Titers were expressed as geometric mean titers calculated on all subjects in the immunogenicity subset of subjects.</description>
        <time_frame>At Days 0 (pre-vaccination Dose 2) and 21 (post-vaccination Dose 2) of the second year (2009/2010) of the study</time_frame>
        <population>The Two-Dose According-To-Protocol cohort for immunogenicity included evaluable subjects for whom data concerning immunogenicity outcome measures were available in terms of antibodies against at least one study vaccine antigen component at Day 21 of the second year of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Group</title>
            <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Hemagglutination-inhibition (HI) Antibody Titer Against Each of the 3 Vaccine Influenza Strains</title>
          <description>Vaccine strains assessed were A/Brisbane/59/2077, A/Uruguay/716/2007 and B/Brisbane/3/2007. Titers were expressed as geometric mean titers calculated on all subjects in the immunogenicity subset of subjects.</description>
          <population>The Two-Dose According-To-Protocol cohort for immunogenicity included evaluable subjects for whom data concerning immunogenicity outcome measures were available in terms of antibodies against at least one study vaccine antigen component at Day 21 of the second year of the study.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1938"/>
                <count group_id="O2" value="1953"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane [Day 0] (N=1932,1942)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9" lower_limit="22.9" upper_limit="25.0"/>
                    <measurement group_id="O2" value="24.3" lower_limit="23.2" upper_limit="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [Day 21] (N=1936,1952)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9" lower_limit="73.6" upper_limit="80.4"/>
                    <measurement group_id="O2" value="70.5" lower_limit="67.1" upper_limit="74.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [Day 0] (N=1932,1942)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.8" lower_limit="54.5" upper_limit="61.3"/>
                    <measurement group_id="O2" value="46.5" lower_limit="43.9" upper_limit="49.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [Day 21] (N=1937,1953)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="256.8" lower_limit="245.3" upper_limit="268.9"/>
                    <measurement group_id="O2" value="162.0" lower_limit="153.9" upper_limit="170.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [Day 0] (N=1933,1942)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" lower_limit="55.6" upper_limit="61.8"/>
                    <measurement group_id="O2" value="56.6" lower_limit="53.6" upper_limit="59.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [Day 21] (N=1938,1953)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199.2" lower_limit="190.8" upper_limit="207.9"/>
                    <measurement group_id="O2" value="171.3" lower_limit="163.6" upper_limit="179.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Hemagglutination-inhibition (HI) Antibody Titer Against Each of the 3 Vaccine Influenza Strains.</title>
        <description>Vaccine strains assessed were A/Brisbane/59/2077, A/Uruguay/716/2007 and B/Brisbane/3/2007. Titers were expressed as geometric mean titers calculated on all subjects for 600 subjects in the persistence subset only.</description>
        <time_frame>At Days 0 (pre-vaccination Dose 1), 21 (post-vaccination Dose 1) and 180 (post-vaccination Dose 1) of the first year (2008/2009) of the study</time_frame>
        <population>The One-Dose According-To-Protocol cohort for persistence included evaluable subjects for whom data concerning immunogenicity outcome measures were available in terms of antibodies against at least one study vaccine antigen component at Day 180 of the first year of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Group</title>
            <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Hemagglutination-inhibition (HI) Antibody Titer Against Each of the 3 Vaccine Influenza Strains.</title>
          <description>Vaccine strains assessed were A/Brisbane/59/2077, A/Uruguay/716/2007 and B/Brisbane/3/2007. Titers were expressed as geometric mean titers calculated on all subjects for 600 subjects in the persistence subset only.</description>
          <population>The One-Dose According-To-Protocol cohort for persistence included evaluable subjects for whom data concerning immunogenicity outcome measures were available in terms of antibodies against at least one study vaccine antigen component at Day 180 of the first year of the study.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
                <count group_id="O2" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane [Day 0] (N=268,265)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" lower_limit="13.7" upper_limit="17.4"/>
                    <measurement group_id="O2" value="13.9" lower_limit="12.4" upper_limit="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [Day 21] (N=268,267)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.4" lower_limit="66.3" upper_limit="85.9"/>
                    <measurement group_id="O2" value="64.5" lower_limit="55.7" upper_limit="74.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [Day 180] (N=268,267)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4" lower_limit="26.8" upper_limit="34.4"/>
                    <measurement group_id="O2" value="28.1" lower_limit="24.8" upper_limit="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [Day 0] (N=268,265)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3" lower_limit="16.5" upper_limit="22.6"/>
                    <measurement group_id="O2" value="17.8" lower_limit="15.3" upper_limit="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [Day 21] (N=268,267)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="275.0" lower_limit="233.1" upper_limit="324.5"/>
                    <measurement group_id="O2" value="165.0" lower_limit="139.0" upper_limit="195.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [Day 180] (N=268,267)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" lower_limit="82.3" upper_limit="116.0"/>
                    <measurement group_id="O2" value="64.0" lower_limit="53.7" upper_limit="76.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [Day 0] (N=268,265)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.3" lower_limit="76.6" upper_limit="104.2"/>
                    <measurement group_id="O2" value="83.8" lower_limit="72.3" upper_limit="97.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [Day 21] (N=268,267)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="573.4" lower_limit="517.5" upper_limit="635.3"/>
                    <measurement group_id="O2" value="478.5" lower_limit="422.4" upper_limit="541.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [Day 180] (N=268,267)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274.6" lower_limit="246.5" upper_limit="305.9"/>
                    <measurement group_id="O2" value="262.3" lower_limit="234.7" upper_limit="293.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Hemagglutination-inhibition (HI) Antibody Titer Against Each of the 3 Vaccine Influenza Strains.</title>
        <description>Vaccine strains assessed were A/Brisbane/59/2077, A/Uruguay/716/2007 and B/Brisbane/3/2007. Titers were expressed as geometric mean titers calculated on all subjects for 600 subjects in the persistence subset only.</description>
        <time_frame>At Days 0 (pre-vaccination Dose 2), 21 (post-vaccination Dose 2) and 180 (post-vaccination Dose 2) of the second year (2009/2010) of the study</time_frame>
        <population>The Two-Dose According-To-Protocol cohort for persistence included evaluable subjects for whom data concerning immunogenicity outcome measures were available in terms of antibodies against at least one study vaccine antigen component at Day 180 of the second year of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Group</title>
            <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Hemagglutination-inhibition (HI) Antibody Titer Against Each of the 3 Vaccine Influenza Strains.</title>
          <description>Vaccine strains assessed were A/Brisbane/59/2077, A/Uruguay/716/2007 and B/Brisbane/3/2007. Titers were expressed as geometric mean titers calculated on all subjects for 600 subjects in the persistence subset only.</description>
          <population>The Two-Dose According-To-Protocol cohort for persistence included evaluable subjects for whom data concerning immunogenicity outcome measures were available in terms of antibodies against at least one study vaccine antigen component at Day 180 of the second year of the study.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane [Day 0] (N=188,177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4" lower_limit="20.3" upper_limit="27.1"/>
                    <measurement group_id="O2" value="25.0" lower_limit="21.3" upper_limit="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [Day 21] (N=188,176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="69.4" upper_limit="92.2"/>
                    <measurement group_id="O2" value="75.0" lower_limit="63.4" upper_limit="88.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [Day 180] (N=189,177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5" lower_limit="24.7" upper_limit="32.8"/>
                    <measurement group_id="O2" value="27.3" lower_limit="23.5" upper_limit="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [Day 0] (N=188,177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.9" lower_limit="56.2" upper_limit="84.5"/>
                    <measurement group_id="O2" value="54.2" lower_limit="44.1" upper_limit="66.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [Day 21] (N=188,176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300.6" lower_limit="254.0" upper_limit="355.7"/>
                    <measurement group_id="O2" value="195.6" lower_limit="165.5" upper_limit="231.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [Day 180] (N=189,177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.7" lower_limit="87.9" upper_limit="127.2"/>
                    <measurement group_id="O2" value="63.6" lower_limit="53.0" upper_limit="76.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [Day 0] (N=189,177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.5" lower_limit="48.8" upper_limit="70.1"/>
                    <measurement group_id="O2" value="56.1" lower_limit="47.0" upper_limit="67.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [Day 21] (N=189,176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225.1" lower_limit="195.5" upper_limit="259.1"/>
                    <measurement group_id="O2" value="191.0" lower_limit="161.3" upper_limit="226.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [Day 180] (N=189,177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.9" lower_limit="106.5" upper_limit="141.7"/>
                    <measurement group_id="O2" value="111.6" lower_limit="95.8" upper_limit="130.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects for HI Antibodies Against Each of the 3 Vaccine Influenza Strains</title>
        <description>In the lot-to-lot subset of subject in the FluGN Group. Vaccine strains assessed were A/Brisbane/59/2077, A/Uruguay/716/2007 and B/Brisbane/3/2007. Seroconversion is defined as the number of subjects with pre-vaccination HI titer (Day 0) &lt; 1:10 and post-vaccination titer (Day 21) â‰¥ 1:40 or a pre-vaccination HI titer (Day 0) â‰¥ 1:10 and fold-increase (post/pre) â‰¥ 4.</description>
        <time_frame>At Day 21 of the first year (2008/2009) of the study.</time_frame>
        <population>The One-Dose According-To-Protocol immunogenicity cohort for the lot-to-lot consistency subset included all subjects from the One-Dose ATP cohort for immunogenicity included in the lot-to-lot subset.</population>
        <group_list>
          <group group_id="O1">
            <title>FluNG Group</title>
            <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
          </group>
          <group group_id="O3">
            <title>FluNG Lot 1 Group</title>
            <description>subjects received 1 dose of FluNG vaccine Lot 1 at Day 0 of the Year 1. They received Dose 2 at Day 0 of the Year 2, again from lot 1. The vaccine was administered intramuscularly in the non-dominant deltoid.</description>
          </group>
          <group group_id="O4">
            <title>FluNG Lot 2 Group</title>
            <description>subjects received 1 dose of FluNG vaccine Lot 2 at Day 0 of the Year 1. They received Dose 2 at Day 0 of the Year 2, again from lot 2. The vaccine was administered intramuscularly in the non-dominant deltoid.</description>
          </group>
          <group group_id="O5">
            <title>FluNG Lot 3 Group</title>
            <description>subjects received 1 dose of FluNG vaccine Lot 3 at Day 0 of the Year 1. They received Dose 2 at Day 0 of the Year 2, again from lot 3. The vaccine was administered intramuscularly in the non-dominant deltoid.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects for HI Antibodies Against Each of the 3 Vaccine Influenza Strains</title>
          <description>In the lot-to-lot subset of subject in the FluGN Group. Vaccine strains assessed were A/Brisbane/59/2077, A/Uruguay/716/2007 and B/Brisbane/3/2007. Seroconversion is defined as the number of subjects with pre-vaccination HI titer (Day 0) &lt; 1:10 and post-vaccination titer (Day 21) â‰¥ 1:40 or a pre-vaccination HI titer (Day 0) â‰¥ 1:10 and fold-increase (post/pre) â‰¥ 4.</description>
          <population>The One-Dose According-To-Protocol immunogenicity cohort for the lot-to-lot consistency subset included all subjects from the One-Dose ATP cohort for immunogenicity included in the lot-to-lot subset.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="539"/>
                <count group_id="O4" value="536"/>
                <count group_id="O5" value="532"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane (N=539,536,532)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="307"/>
                    <measurement group_id="O4" value="298"/>
                    <measurement group_id="O5" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay (N=539,536,532)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="471"/>
                    <measurement group_id="O4" value="461"/>
                    <measurement group_id="O5" value="455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane (N=539,536,532)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="389"/>
                    <measurement group_id="O4" value="350"/>
                    <measurement group_id="O5" value="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited symptoms: During the 7-day post-vaccination period the first year (2008/2009) and the second year (2009/2010). SAEs: During the entire study period (during the 365 days of follow-up after each vaccination at Year 2008/2009 and Year 2009/2010)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>FluNG Group</title>
          <description>subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
        </group>
        <group group_id="E2">
          <title>Fluarix Group</title>
          <description>subjects received 2 doses (1 dose per season) of Fluarixâ„¢ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4071" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4066" subjects_at_risk="21802"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21802"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="211" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="178" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="169" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="167" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="147" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="153" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal angiodysplasia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21802"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21802"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Gastroduodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="228" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="226" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways diseas</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21802"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Non-hodgkinâ€™s lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Renal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Breast cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Ovarian neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="180" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Vascular dementia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Dementia alzheimerâ€™s type</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Parkinsonâ€™s disease</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Cerebral arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Vascular encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Urinary bladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Bladder neck obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21802"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21893"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="21802"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1225" subjects_at_risk="2988"/>
                <counts group_id="E2" subjects_affected="477" subjects_at_risk="2968"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <description>During the 7-day (Days 0-6) post-vaccination period, the first year (2008/2009)</description>
                <counts group_id="E1" subjects_affected="1225" subjects_at_risk="2988"/>
                <counts group_id="E2" subjects_affected="477" subjects_at_risk="2968"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <description>During the 7-day (Days 0-6) post-vaccination period, the first year (2008/2009)</description>
                <counts group_id="E1" subjects_affected="240" subjects_at_risk="2988"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="2968"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <description>During the 7-day (Days 0-6) post-vaccination period, the first year (2008/2009)</description>
                <counts group_id="E1" subjects_affected="189" subjects_at_risk="2988"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="2968"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>During the 7-day (Days 0-6) post-vaccination period, the second year (2009/2010)</description>
                <counts group_id="E1" subjects_affected="998" subjects_at_risk="2441"/>
                <counts group_id="E2" subjects_affected="440" subjects_at_risk="2488"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <description>During the 7-day (Days 0-6) post-vaccination period, the second year (2009/2010)</description>
                <counts group_id="E1" subjects_affected="212" subjects_at_risk="2441"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="2488"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <description>During the 7-day (Days 0-6) post-vaccination period, the second year (2009/2010)</description>
                <counts group_id="E1" subjects_affected="173" subjects_at_risk="2441"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="2488"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>During the 7-day (Days 0-6) post-vaccination period, the first year (2008/2009)</description>
                <counts group_id="E1" subjects_affected="391" subjects_at_risk="2986"/>
                <counts group_id="E2" subjects_affected="239" subjects_at_risk="2968"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>During the 7-day (Days 0-6) post-vaccination period, the first year (2008/2009)</description>
                <counts group_id="E1" subjects_affected="646" subjects_at_risk="2986"/>
                <counts group_id="E2" subjects_affected="417" subjects_at_risk="2968"/>
              </event>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <description>During the 7-day (Days 0-6) post-vaccination period, the first year (2008/2009)</description>
                <counts group_id="E1" subjects_affected="197" subjects_at_risk="2986"/>
                <counts group_id="E2" subjects_affected="165" subjects_at_risk="2968"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>During the 7-day (Days 0-6) post-vaccination period, the first year (2008/2009)</description>
                <counts group_id="E1" subjects_affected="474" subjects_at_risk="2986"/>
                <counts group_id="E2" subjects_affected="333" subjects_at_risk="2968"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>During the 7-day (Days 0-6) post-vaccination period, the first year (2008/2009)</description>
                <counts group_id="E1" subjects_affected="547" subjects_at_risk="2986"/>
                <counts group_id="E2" subjects_affected="302" subjects_at_risk="2968"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <description>During the 7-day (Days 0-6) post-vaccination period, the first year (2008/2009)</description>
                <counts group_id="E1" subjects_affected="245" subjects_at_risk="2986"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="2968"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>During the 7-day (Days 0-6) post-vaccination period, the second year (2009/2010)</description>
                <counts group_id="E1" subjects_affected="258" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="176" subjects_at_risk="2489"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>During the 7-day (Days 0-6) post-vaccination period, the second year (2009/2010)</description>
                <counts group_id="E1" subjects_affected="457" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="318" subjects_at_risk="2489"/>
              </event>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <description>During the 7-day (Days 0-6) post-vaccination period, the second year (2009/2010)</description>
                <counts group_id="E1" subjects_affected="137" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="124" subjects_at_risk="2489"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>During the 7-day (Days 0-6) post-vaccination period, the second year (2009/2010)</description>
                <counts group_id="E1" subjects_affected="342" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="237" subjects_at_risk="2489"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>During the 7-day (Days 0-6) post-vaccination period, the second year (2009/2010)</description>
                <counts group_id="E1" subjects_affected="380" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="209" subjects_at_risk="2489"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <description>During the 7-day (Days 0-6) post-vaccination period, the second year (2009/2010)</description>
                <counts group_id="E1" subjects_affected="189" subjects_at_risk="2436"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="2489"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

